Carcinoma In Situ — Trials

Carcinoma In Situ — Trials · CancerIndex

Clinical trials

Registered studies

274 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 72
Recruiting: 35
Ph III recruiting: 4
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (41)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06390111	A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.(ABLE-42)	withdrawn	Phase 4	0	Ferring PharmaceuticalsINDUSTRY	1	Nov 22, 2024	clinicaltrials

Data updated 23 days agoSource updated Nov 22, 2024source: clinicaltrials